ScreenerHero
DEVADeva Holding A.S.
BIST · TR · Healthcare · Drug Manufacturers - Specialty & Generic · deva.com.tr
88.40TRY-0.84%Mkt Cap: 426.41M $P/E: —

Deva Holding A.S. manufactures, markets, and sells pharmaceutical products in Turkey. The company offers antineoplastic and immunomodulating agents; dermatological products; systemic hormanal preparations; anti-infective…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap426.41M $
Enterprise Value490.96M $
Revenue (TTM)482.40M $
Gross Profit150.77M $
Net Income (TTM)-19.30M $
Revenue/Share2.412 USD
Last Price88.40 TRY
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3.1K
CountryTR
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA7.28
EV/Revenue1.02
P/S0.88
P/B0.62
EPS (TTM)-4.04
EPS (Forward)—
52W Range
57.5093% of range90.80
52W High90.80 TRY
52W Low57.50 TRY
Profitability
Gross Margin32.76%
Oper. Margin18.56%
EBITDA Margin13.97%
Profit Margin-4.19%
ROE-3.07%
ROA-2.14%
Growth
Revenue Growth8.40%
Earnings Growth-7.00%
Cash Flow & Leverage
Operating CF126.37M $
CapEx (TTM)56.55M $
FCF Margin-16.07%
FCF Yield-18.18%
Net Debt64.56M $
Net Debt/EBITDA0.96
Balance Sheet
Debt/Equity0.23
Current Ratio2.10
Quick Ratio1.24
Book Value/Sh144.21 TRY
Cash/Share17.85 TRY
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 TRY
Div. Yield—
5Y Avg Yield0.35%
Payout Ratio0.00%
Ex-Div DateJun 25, 2024
Pay Date—
Splits
Last Split1:1000
Split DateJan 3, 2005
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.200.02M
Float35.59M
Insiders82.20%
Institutions0.26%
Technical
SMA 5071.96 (+22.9%)
SMA 20067.05 (+31.8%)
Beta-0.13
S&P 52W Chg18.16%
Avg Vol (30d)687.95K
Avg Vol (10d)935.43K
Technical Indicators
RSI (14)79.8
MACD3.2023
MACD Signal1.3556
MACD Hist.+1.8467
BB Upper85.98 TRY
BB Middle74.27 TRY
BB Lower62.56 TRY
BB Width31.53%
ATR (14)3.392 TRY
Vol Ratio (20d)3.00x